Compare DSY & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DSY | ANL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 52.0M |
| IPO Year | N/A | 2023 |
| Metric | DSY | ANL |
|---|---|---|
| Price | $0.34 | $1.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 136.4K | 25.3K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,323,356.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.62 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $0.32 | $0.88 |
| 52 Week High | $7.33 | $2.99 |
| Indicator | DSY | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 18.59 | 50.39 |
| Support Level | $0.34 | $0.88 |
| Resistance Level | $0.43 | $1.59 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 18.38 | 68.37 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.